Boomfish Wealth Group LLC Invests $273,000 in Pfizer Inc. (NYSE:PFE)

Boomfish Wealth Group LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 9,445 shares of the biopharmaceutical company’s stock, valued at approximately $273,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Scarborough Advisors LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $124,000. Creekmur Asset Management LLC bought a new stake in Pfizer in the fourth quarter worth $32,000. SageView Advisory Group LLC boosted its position in Pfizer by 2.2% during the fourth quarter. SageView Advisory Group LLC now owns 45,186 shares of the biopharmaceutical company’s stock valued at $1,221,000 after buying an additional 973 shares during the period. Stonehearth Capital Management LLC grew its stake in shares of Pfizer by 16.8% during the first quarter. Stonehearth Capital Management LLC now owns 10,463 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 1,506 shares during the last quarter. Finally, Cravens & Co Advisors LLC increased its holdings in shares of Pfizer by 9.6% in the first quarter. Cravens & Co Advisors LLC now owns 19,135 shares of the biopharmaceutical company’s stock worth $531,000 after buying an additional 1,681 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Down 0.3 %

PFE stock opened at $29.08 on Tuesday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The company has a market capitalization of $164.78 billion, a price-to-earnings ratio of -484.67, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. The business’s 50 day moving average price is $29.02 and its two-hundred day moving average price is $28.40. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.78%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.